Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled

Part A 16-week proof-of-concept data anticipated in mid-2025

Read more at globenewswire.com